Senti Biosciences Holdings, Inc. (SNTI) — Institutional Holders, Q2 2026
19 institutional investment managers reported a SNTI position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $5.4M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
SNTI in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- CITADEL ADVISORSNew · +107,100 sh+$117.8K
- JANE STREET GROUPNew · +52,530 sh+$57.8K
- Virtu FinancialNew · +22,795 sh+$25.1K
- NORTHERNAdded · +15,376 sh+$16.9K
- Tower Research Capital (TRC)New · +7,344 sh+$8.1K
Biggest sellers
- Nantahala Capital ManagementSold out · -888,000 sh-$976.8K
- BlackRockTrimmed · -21,070 sh-$23.2K
- GEODE CAPITAL MANAGEMENTTrimmed · -19,978 sh-$22.0K
- HRT FINANCIALSold out · -14,844 sh-$16.3K
SNTI 13F holders ranked 1–19 of 19
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | NEA Management Company#1 · 3,775,615 sh | 3,775,615 | $4.2M | 0.26% | 0.0% |
| 2 | VANGUARD CAPITAL MANAGEMENT#2 · 537,504 sh | 537,504 | $591.3K | 0.00% | 0.0% |
| 3 | GEODE CAPITAL MANAGEMENT#3 · 187,065 sh | 187,065 | $205.8K | 0.00% | -9.6% |
| 4 | CITADEL ADVISORS#4 · 107,100 sh | 107,100 | $117.8K | 0.00% | New |
| 5 | VANGUARD FIDUCIARY#5 · 91,193 sh | 91,193 | $100.3K | 0.00% | 0.0% |
| 6 | JANE STREET GROUP#6 · 52,530 sh | 52,530 | $57.8K | 0.00% | New |
| 7 | Menlo Ventures Management, L.P.#7 · 35,737 sh | 35,737 | $39.3K | 0.01% | 0.0% |
| 8 | NORTHERN#8 · 32,154 sh | 32,154 | $35.4K | 0.00% | +91.6% |
| 9 | XTX Topco Ltd#9 · 23,610 sh | 23,610 | $26.0K | <0.01% | +36.7% |
| 10 | Virtu Financial#10 · 22,795 sh | 22,795 | $25.0K | <0.01% | New |
| 11 | UBS Group AG#11 · 14,432 sh | 14,432 | $15.9K | 0.00% | +67.1% |
| 12 | STATE STREET#12 · 10,010 sh | 10,010 | $11.0K | 0.00% | 0.0% |
| 13 | Tower Research Capital (TRC)#13 · 7,344 sh | 7,344 | $8.1K | <0.01% | New |
| 14 | BlackRock#14 · 4,004 sh | 4,004 | $4.4K | 0.00% | -84.0% |
| 15 | ROYAL BANK OF CANADA#15 · 4,015 sh | 4,015 | $4.0K | 0.00% | New |
| 16 | BARCLAYS PLC#16 · 768 sh | 768 | $845.00 | 0.00% | New |
| 17 | SBI Securities , Ltd.#17 · 334 sh | 334 | $367.00 | — | 0.0% |
| 18 | MORGAN STANLEY#18 · 169 sh | 169 | $186.00 | 0.00% | +5.6% |
| 19 | Caitong International Asset Management , Ltd#19 · 1 sh | 1 | $1.00 | 0.00% | 0.0% |
Funds that sold out of SNTI in Q2 2026 (2)
Held SNTI at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Nantahala Capital Management888,000 sh | 888,000 | $721.1K |
| HRT FINANCIAL14,844 sh | 14,844 | $12.0K |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.